Global North America Continuous Glucose Monitoring Market Size, Share and Trends Analysis
North America CGM market valued at US$9.5 Bn in 2023, forecast to US$36.1 Bn by 2032 at 16.0% CAGR.
$9.5B
$36.1B
16%
North America
Executive Summary
The North America continuous glucose monitoring market was US$9.5 Bn in 2023 and is projected to reach US$36.1 Bn by 2032, expanding at a 16.0% CAGR. Growth is driven by rising diabetes prevalence, favorable reimbursement policies, and rapid adoption of wearable and implantable CGM systems. Dexcom and Abbott dominate the competitive landscape, while Medtronic, Senseonics, and Roche strengthen the ecosystem through integrated insulin‑delivery solutions.
Key Highlights
North America CGM market to exceed US$36 Bn by 2032.
Wearable sensors dominate with 60% share, driven by convenience.
Dexcom and Abbott together control over 70% of regional revenue.
Market Overview
Market Context
North America leads global CGM adoption, fueled by high diabetes prevalence, advanced reimbursement frameworks, and rapid technology upgrades. Wearable devices are most common, while implantable and smartphone‑connected segments are expanding quickly.
North America accounts for roughly 45% of the global CGM market, propelled by high diabetes incidence and advanced healthcare infrastructure. Wearable sensors lead adoption, with implantable and smartphone‑connected devices gaining traction.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$9.5B
Forecast (2032)
$36.1B
CAGR (2024-2032)
16%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $9.50B |
| 2024 | $11.02B |
| 2025 | $12.78B |
| 2026 | $14.83B |
| 2027 | $17.20B |
| 2028 | $19.95B |
| 2029 | $23.15B |
| 2030 | $26.85B |
| 2031 | $31.14B |
| 2032 | $36.13B |
Applying a 16.0% CAGR from the 2023 base of US$9.5 Bn yields a US$36.1 Bn market by 2032. Growth will be sustained by sensor innovation, broader payer coverage, and entry of consumer‑focused CGM products.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 45.0% | 16.5% | United States |
| Europe | 30.0% | 14.0% | Germany |
| Asia Pacific | 25.0% | 18.0% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising diabetes prevalence and obesity rates
- Improved sensor accuracy and miniaturization
- Favorable payer reimbursement policies
Market Segmentation
| Segment | Share |
|---|---|
| Wearable CGMSkin‑adhered sensors providing real‑time glucose readings. | 60.0% |
| Implantable CGMSubcutaneous implants offering continuous 180‑day monitoring. | 25.0% |
| Smartphone‑connected CGMDevices that pair directly with mobile apps for data sharing. | 15.0% |
| Total | 100.0% |
By End User
- Hospitals
- Home Care
- Clinics
Regional Analysis
North America
Lead: United StatesLargest market due to high adoption, strong reimbursement, and leading OEMs.
Europe
Lead: GermanyGrowing demand driven by EU MDR compliance and expanding diabetes programs.
Asia Pacific
Lead: ChinaFastest growth region owing to rising diabetic population and digital health investments.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 68.0% | +16.2% |
| Germany | 10.0% | +13.5% |
| China | 7.0% | +19.0% |
Competitive Landscape
Dexcom
United States
Dominates with G7 and G6 systems; ~35‑40% global revenue share and broad PBM coverage.
Leading CGM innovator with real‑time continuous monitoring platforms.
Abbott Laboratories
United States
Strong with FreeStyle Libre franchise; targeting US$10 Bn Libre sales by 2028.
Major diagnostics firm offering the FreeStyle Libre flash‑monitoring system.
Medtronic
Ireland
Integrated pump‑CGM solutions; MiniMed 780G and Simplera Sync sensor.
Integrated insulin‑pump and CGM provider for diabetes management.
Recent Developments
Launched G7 with enhanced accuracy and Bluetooth connectivity
Introduced consumer CGM brand Lingo for wellness market
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews
- Surveys
Secondary research
- Industry reports
- Company financials
Validation: Triangulation method
Strategic Takeaways
Target Dexcom and Abbott for stable growth; watch Medtronic's integrated pump‑CGM synergy.
Prioritize wearable CGM integration with digital health platforms to capture expanding home‑care segment.
Expanding CGM reimbursement can reduce long‑term diabetes complications and costs.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Medical DevicesGlobal Continuous Glucose Monitoring Market$9.8B · 15.8% CAGR
- Medical DevicesGlobal Asia Pacific Continuous Glucose Monitoring Market$10.0B · 20.9% CAGR
- Medical DevicesGlobal Europe Continuous Glucose Monitoring Market$10.0B · 19.6% CAGR
- Medical DevicesGlobal United States Continuous Glucose Monitoring Market$3.8B · 16.5% CAGR
- Medical DevicesNorth America Surgical Robotics Market$7.5B · 14.8% CAGR
- Medical DevicesGlobal North America Wearable Medical Devices Market$16.5B · 13.5% CAGR